# Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant

> **NCT00507689** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 40 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** FTC/TDF
- **DRUG:** Hepatitis B Immunoglobulin (HBIg)

## Key facts

- **NCT ID:** NCT00507689
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00507689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00507689, "Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00507689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*